WuXi Biologics' "Golden Funnel" value blooms, CRDMO fully powered up

Ask AI · How does WuXi Biologics’ CRDMO model build an industry moat?

By | Yun Tan

The CRDMO model is in full swing, with the value of the “golden funnel” shining brightly, precisely hitting the high-demand trends of dual/multiple antibodies and ADCs. WuXi Biologics, the leading CXO in biopharmaceuticals, demonstrates its industry dominance in its 2025 performance.

For its investors, this performance explosion is not surprising: in 2025, the company achieved record highs in revenue and profit, with revenue growing 16.7% year-on-year to 21.8 billion yuan; gross margin lifted by 5 percentage points to 46%; net profit attributable to shareholders soared 46.3% to 4.9 billion yuan; adjusted net profit reached 6.6 billion yuan, up 22% year-on-year; and free cash flow grew over 70% year-on-year to 2.3 billion yuan.

Core indicators are all in the green, delivering an unexpectedly strong report card. Meanwhile, WuXi Biologics expects revenue in 2026 to achieve a year-on-year growth of 13%-17%.

With high technical barriers forming a moat, coupled with the global biopharmaceutical R&D boom, WuXi Biologics’ explosive growth potential and dominance in its field continue to rise, revealing increasing long-term value.

【CRDMO Model Dominance, Building Competitive Barriers】

There are many competitors in the CXO space, but looking globally, WuXi Biologics is the only genuinely open, end-to-end integrated biopharmaceutical CRDMO platform that can provide customers with full-chain services from early discovery research ®, development (D) to commercial production (M).

It’s like paving a “highway for biopharmaceutical R&D and production” for customers. Regardless of the stage of a customer’s project, solutions can be found at WuXi Biologics: considering development and production feasibility during the research phase, leveraging leading technology to seize first-mover advantages; incorporating commercialization thinking during the development phase, balancing quality, speed, and cost to enhance product accessibility; collaborating with customers on commercialization plans during the production phase to help products successfully complete BLA submissions and achieve excellent market launches.

More competitors still remain at the CMO or CDMO stage. Companies like Samsung Biologics and Lonza are also CDMO players, unable to independently meet the complex demands of customers transitioning molecules from the lab to commercialization.

Currently, globally, there are very few large molecule CXO companies that truly possess full-chain capabilities. Even if peers have similar aspirations, they are fundamentally unable to achieve them due to limitations in technological innovation, talent reserves, and the reach of their capabilities. WuXi Biologics relies on a powerful technical platform, a global network, professional talent, and lean management to lead biopharmaceutical development through perfect execution.

It is precisely the foundational construction of the CRDMO business model that enables WuXi Biologics to navigate the market with ease, achieving another performance explosion in 2025. In 2025, WuXi Biologics added 209 new projects, setting a historical record, bringing the total number of projects to 945. This is one of the industry’s largest complex biopharmaceutical product pipelines. With a continuous influx of projects into the CRDMO platform, WuXi Biologics continues to innovate in technology and evolve its capabilities. The appeal to customers has shifted from the most basic industry factors of “efficiency and cost” to the scarce value of “cutting-edge technology implementation capabilities.” This is evidenced by the fact that two-thirds of the new projects signed by WuXi Biologics in 2025 are dual antibodies and antibody-drug conjugates (ADCs). For these complex molecules that embody commercial ambitions and urgent clinical needs for patients, customers “vote with their feet” by collaborating with WuXi Biologics, adding a layer of security to their pipelines.

In addition, WuXi Biologics has a strategy referred to as “following and winning molecules.” This means that within the integrated CRDMO platform, early projects can progress along the R-D-M route to the commercial production stage, and these customers have extremely high stickiness, with project retention rates exceeding 95%. On the other hand, projects that transition from external sources to WuXi Biologics at different stages are referred to as “winning molecule” projects, which best demonstrate customers’ trust in WuXi Biologics’ technology and services. In 2025, a total of 23 new drug IND projects transitioned from external sources, including 6 late-stage clinical projects. Since 2018, WuXi Biologics has won a total of 112 comprehensive projects. The external projects transitioning in further attest to the company’s strength and customer trust, which will bring significant revenue in the future, becoming an important performance growth engine for WuXi Biologics.

【Golden Funnel, Value Unleashed】

Whether following or winning molecules, they advance in an orderly manner within the WuXi Biologics CRDMO platform, forming a unique “golden funnel.” As various molecules progress along the R-D-M route, their value continues to amplify.

In 2025, 71 projects advanced from preclinical to clinical phase 1, and 22 projects advanced from clinical phase 1 to phase 2. During the same period, WuXi Biologics supported the production of 74 clinical phase 3 and 25 commercialization projects.

▲ Number of projects in WuXi Biologics’ CRDMO “golden funnel”

Among these, the R-end business can be understood as the flow entry point of the funnel, screening and delivering quality projects for subsequent phases. At the same time, the R-end business also demonstrates high value potential and direct monetization ability, enhancing the visibility of the company’s long-term high-profit growth.

For example, in 2022, WuXi Biologics reached a partnership with GSK, where GSK will gain exclusive rights to up to four TCE dual/multiple antibodies from WuXi Biologics, which will receive a $40 million upfront payment and up to $1.46 billion in milestone payments, and will be eligible for sales royalties after product launch.

To date, WuXi Biologics’ CD3 TCE platform has been widely applied by multinational companies and Chinese biopharmaceutical firms, including Vertex, Merck, GSK, and Chengdu Tianqing. The early strategic investments in this platform from 2016 to 2019 have now generated over $200 million in revenue.

In 2025, the potential total milestone payments from WuXi Biologics’ research collaboration projects could exceed $4 billion. By the end of 2025, WuXi Biologics’ research business had empowered over 50 projects entitled to milestone payments and sales royalties, laying a foundation for long-term high-profit growth.

▲ WuXi Biologics’ forward-looking layout of the CD3 TCE platform opens up tens of billions of dollars in growth space

The D-end (development) connects the previous and subsequent phases, growing steadily. WuXi Biologics has the capacity to submit 200 INDs and 20 BLAs/MAAs annually. In 2025, the number of new development projects reached a new high, with two-thirds being dual antibodies and ADC projects, both growing about 30%. The proportion of complex biopharmaceutical molecule projects exceeds 50% of the company’s total project count, further demonstrating the company’s dominance in the complex biopharmaceutical field.

The M-end (production) ensures that once project products enter commercialization, they contribute significant stable revenue annually, and as sales ramp up, profits are continuously released. PPQ is the “production permit” for commercial production. The overall number of PPQs at the company shows an upward trend, with 28 completed in 2025, a 75% increase year-on-year, and 34 planned for 2026, setting a historical record. Moreover, the number has doubled over two years (16-28-34), locking in commercial revenue for the next 1-3 years and becoming the strongest leading indicator of performance certainty.

▲ WuXi Biologics’ PPQ numbers steadily increase, supporting future CMO growth

It should also be noted that WuXi Biologics covers all biopharmaceutical sub-sectors with its R, D, and M business segments, among which dual/multiple antibodies and ADC projects are growing the fastest. This reflects the hot market demand; according to Frost & Sullivan, the global dual antibody market is expected to reach $98 billion by 2030, while the ADC market is projected to reach $66.2 billion during the same period.

▲ Three high-growth molecule types assist WuXi Biologics in accelerating growth

Dual/multiple antibodies have become WuXi Biologics’ fastest-growing and most profitable core growth engine, contributing a year-on-year increase of 120% in 2025. Currently, there are 196 dual/multiple antibody projects within WuXi Biologics’ platform, including 3 commercialization projects, all of which are high-potential assets. It is foreseeable that dual/multiple antibody projects will continue to drive high-speed growth in WuXi Biologics’ future performance.

【Diverse Advantages Driving Long-Term Value】

The record number of new projects not only boosts market confidence but also lays the foundation for future growth.

However, from the dual dimensions of industry development and corporate growth, WuXi Biologics’ long-term value is not solely supported by the advantages of a single CRDMO model, but rather is constructed through a multi-dimensional “compound moat” of innovative technology, global layout, and management efficiency.

In terms of innovative technology, WuXi Biologics relies on numerous proprietary high-barrier technology platforms, placing it at the forefront of the complex biopharmaceutical market. For instance, in the dual/multiple antibody field, there are the WuXiBody™ and SDArBody™ platforms, while in the ADC field, the WuXiDARx™ conjugation technology platform, X-LinC linker technology, and WuXiTecan-1 and WuXiTecan-2 payload conjugate technologies have all shown “verifiable achievements,” significantly shortening R&D cycles and reducing risks for customers.

In 2025, WuXi Biologics launched the WuXia™ TrueSite targeted integrated cell line platform and the WuXiHigh™ 2.0 high-concentration formulation platform. The former achieves an average monoclonal antibody expression level exceeding 8 g/L at the “source” cell line construction stage of drug development, greatly enhancing efficiency and stability; the latter addresses the core pain points of high-concentration formulation development, increasing protein concentration to 240 mg/mL.

In terms of global layout, the construction of WuXi Biologics’ global network and supply system not only enables a rapid response to global customer needs but also effectively mitigates operational risks arising from geopolitical issues. About half of the new projects signed in 2025 still come from the United States, where the U.S. market accounts for 58.1% of total revenue, and the European market accounts for 23.1%. This showcases the company’s hard power in technology, quality, and service, dispelling previous market concerns. Additionally, the company has established commercial production capacity in major global markets, possessing deep global regulatory compliance experience, becoming an important endorsement for customers looking to enter the global market.

In terms of management and operations, the dual empowerment of digitalization and lean operations has allowed WuXi Biologics to maintain efficiency and cost advantages during scaled development, making it the “efficiency king” in the CXO space. For example, core laboratory management systems, computer modeling, and intelligent production systems like electronic batch record systems (EBR) and manufacturing execution systems (MES) not only enhance production and operational efficiency but also ensure product quality. The WBS (WuXi Biologics Business Management System) improvement projects directly enhance gross margins through increased labor efficiency, cost savings, and process optimization.

In the global wave of biopharmaceutical R&D, the synergistic effect of WuXi Biologics’ diverse advantages is continuously translating into certainty of performance growth and long-term value.

For WuXi Biologics, even though the annual stock price has nearly increased by 80% in 2025, the company is still in a state of undervaluation, with recent average PE valuations significantly deviating from the three-year valuation mean, overall positioned in the bottom range of three-year valuations, and also lower than the industry average valuation level.

Since the beginning of this year, well-known institutions such as JPMorgan Chase, Morgan Stanley, UBS, Citi, Bank of America, and Nomura have raised the company’s target price to the HKD 45-51 range based on WuXi Biologics’ strong growth in project scale and better-than-expected performance.

Major firms also generally believe that the impact of geopolitical risks on the valuations of Chinese CXO companies has significantly diminished. For example, Goldman Sachs stated that outsourcing remains an indispensable part of the biopharmaceutical innovation and manufacturing strategy, and geopolitical noise has not altered the long-term economic logic supporting ongoing externalization.

It is clear that as the certainty of performance growth continues to materialize, the valuation recovery of WuXi Biologics is well-supported by solid logical foundations. In the global biopharmaceutical CXO space, its leading position and long-term value will continue to stand out.

Disclaimer

This article involves content related to publicly listed companies, based on the author’s personal analysis and judgment of information publicly disclosed by the listed company in accordance with its legal obligations (including but not limited to interim announcements, periodic reports, and official interactive platforms); the information or opinions in the article do not constitute any investment or other business advice, and Market Value Observation assumes no responsibility for any actions taken based on this article.

——END——